Back
EGFR-mutated mNSCLC: Updates from WCLC 2025
Experts discuss key WCLC updates in the diagnosis and treatment of EGFR-mutated NSCLC. The conversation highlights patient burden with frontline combination regimens and reviews pivotal data from the MARIPOSA and FLAURA2 trials.
EGFR-mutated mNSCLC: Updates from WCLC 2025
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
4
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
5